The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation (original) (raw)
- Original Article
- Published: 23 December 1999
Complications
- HM Kingman1,
- C Kelly1,
- GS Taylor2,
- EO Caul2,
- D Grier3,
- J Moppett1,
- ABM Foot1,
- JM Cornish1,
- A Oakhill1,
- CG Steward1,
- DH Pamphilon1 &
- …
- DI Marks1
Bone Marrow Transplantation volume 24, pages 1315–1322 (1999)Cite this article
- 814 Accesses
- 88 Citations
- Metrics details
Abstract
Respiratory syncytial virus (RSV) is known to cause acute lung injury in the immunocompromised host, especially recipients of bone marrow allografts. Specific prognostic factors for the development of severe life-threatening disease remain to be identified as does the optimum treatment of established disease. Over a 5-year period the incidence and outcome of RSV in BMT recipients was analysed retrospectively. Prognostic factors assessed included type of transplant, engraftment status at the time of infection, the presence of lower respiratory tract disease, viral genotype and treatment received. During the study period, 26 of 336 (6.3%) allogeneic stem-cell recipients were identified as having RSV. Five patients (19.2%) died as a direct result of RSV. One patient died secondary to an intracranial bleed with concomitant RSV. There were four patients with graft failure (two primary and two secondary) attributable to the presence of RSV, two of whom subsequently died of infections related to prolonged myelosuppression. The presence of lower respiratory tract infection and a poor overall outcome was the only statistically significant association. Unrelated donor transplants and AML as the underlying disease appeared to be associated with a poorer outcome. Engraftment status, viral genotype and RSV treatment received did not correlate with outcome. We conclude that future studies are required to identify early sensitive and reproducible prognostic factors of RSV in the immunocompromised host. The roles of intravenous and nebulised ribavirin need to be clarified by prospective controlled trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Bone Marrow Transplant Unit, Bristol Royal Hospital for Sick Children, United Bristol Healthcare Trust, Bristol, UK
AJ McCarthy, HM Kingman, C Kelly, J Moppett, ABM Foot, JM Cornish, A Oakhill, CG Steward, DH Pamphilon & DI Marks - Department of Virology, Public Health Laboratory Services, Bristol, UK
GS Taylor & EO Caul - Department of Radiology, Bristol Royal Hospital for Sick Children, United Bristol Healthcare Trust, Bristol, UK
D Grier
Authors
- AJ McCarthy
You can also search for this author inPubMed Google Scholar - HM Kingman
You can also search for this author inPubMed Google Scholar - C Kelly
You can also search for this author inPubMed Google Scholar - GS Taylor
You can also search for this author inPubMed Google Scholar - EO Caul
You can also search for this author inPubMed Google Scholar - D Grier
You can also search for this author inPubMed Google Scholar - J Moppett
You can also search for this author inPubMed Google Scholar - ABM Foot
You can also search for this author inPubMed Google Scholar - JM Cornish
You can also search for this author inPubMed Google Scholar - A Oakhill
You can also search for this author inPubMed Google Scholar - CG Steward
You can also search for this author inPubMed Google Scholar - DH Pamphilon
You can also search for this author inPubMed Google Scholar - DI Marks
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
McCarthy, A., Kingman, H., Kelly, C. et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation.Bone Marrow Transplant 24, 1315–1322 (1999). https://doi.org/10.1038/sj.bmt.1702078
- Received: 19 April 1999
- Accepted: 22 July 1999
- Published: 23 December 1999
- Issue Date: 01 December 1999
- DOI: https://doi.org/10.1038/sj.bmt.1702078